Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma

Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a highly aggressive malignancy with a poor prognosis. However, there are no consensus treatment guidelines, and decisions are usually extrapolated from intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC). Given...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Nan, Lei, Chuan-Fen, Tan, Si-Rui, Huang, Qi-Yue, Zhang, Shun-Yu, Liang, Zheng-Xin, Gou, Hong-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603266/
https://www.ncbi.nlm.nih.gov/pubmed/37900166
http://dx.doi.org/10.3389/fphar.2023.1190967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603266/
https://www.ncbi.nlm.nih.gov/pubmed/37900166
http://dx.doi.org/10.3389/fphar.2023.1190967

Ejemplares similares